| Number | Title | Publication |
| GOG-0248 | Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma | |
| GOG-0229I | Phase II Study of Brivanib Alaninate in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229G | Phase II Study of Bevacizumab and Temsirolimus in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229F | Phase II Study of VEGF Trap in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229E | Phase II Study of Bevacizumab in Patients With Recurrent or Persistent Endometrial Cancer | |
| GOG-0229D | Phase II Study of Lapatinib in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229C | Phase II Study of Gefitinib in Patients With Persistent or Recurrent Endometrial Carcinoma | |
| GOG-0229B | Phase II Study of Thalidomide in Patients With Recurrent or Persistent Endometrial Cancer | PMID 17306350 |
| GOG-0224 | Phase II Randomized Study of Megestrol Acetate in Patients With Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia | |
| GOG-0211 | Phase II Pilot Study of Medroxyprogesterone in Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | |
| GOG-0209 | Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer | |
| GOG-0189 | Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Tamoxifen and Megestrol in Patients With Stage III or IV or Recurrent Endometrial Cancer | |
| GOG-0188 | Phase II Study of Fulvestrant in Patients With Newly Recurrent, Persistent, or Metastatic Endometrial Cancer | |
| GOG-0184 | Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma | |
| GOG-0181B | Phase II Study of Trastuzumab (Herceptin®) in Patients With Advanced, Recurrent, or Persistent Endometrial Adenocarcinoma | PMID 1984088 |
| GOG-0177 | Phase III Randomized Study of Doxorubicin/Cisplatin With or Without Paclitaxel and Filgrastim (G-CSF) Support in Patients with Stage III, Stage IV, or Recurrent Endometrial Cancer | |
| GOG-0163 | Phase III Randomized Study of Doxorubicin/Cisplatin vs Doxorubicin/Paclitaxel/G-CSF for Primary Stage III/IV or Recurrent Endometrial Carcinoma | |
| GOG-0156 | Phase III Randomized Study of Adjuvant Pelvic Irradiation vs DOX/CDDP for Stage IB/IC/IIA/IIB Endometrial Carcinoma | Terminated |
| GOG-0137A | Phase III Randomized Study of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma | |
| GOG-0129Q] | Phase II Study of Gemcitabine Hydrochloride in Patients With Recurrent or Persistent Endometrial Adenocarcinoma | |
| GOG-0129P | Phase II Study of Ixabepilone in Patients With Recurrent or Persistent Endometrial Adenocarcinoma | PMID 19451430 |
| GOG-0129O | Phase II Study of Pemetrexed Disodium in Patients With Persistent or Recurrent Endometrial Adenocarcinoma | PMID 19804902 |
| GOG-0129N | Phase II Study of Docetaxel in Patients With Recurrent or Persistent Endometrial Carcinoma | PMID 18675446 |
| GOG-0129M | Phase II Study of Flavopiridol in Patients With Recurrent or Persistent Endometrial Carcinoma | PMID 15978659 |
| GOG-0129K | Phase II Study of Oxaliplatin in Patients With Persistent or Recurrent Endometrial Carcinoma | PMID 16712905 |
| GOG-0087J | Phase II Study of Doxorubicin HCl Liposome in Patients With Recurrent or Advanced Uterine Sarcoma | PMID 15721421 |
| GOG-0086M | Phase II Study of Doxorubicin HCl Liposome in Patients With Advanced or Recurrent Endometrial Cancer | PMID 15975638 |
| GOG-0026A | Master Protocol Template for Individual Phase II Studies of New Drug Therapies in Patients With Metastatic or Recurrent Gynecologic Malignancies | |
| GOG-9908 | Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer | PMID 19135232 |
| GOG-9907 | Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer | PMID 18962846 |
| GOG-9905 | Phase III Randomized Study of Adjuvant Radiotherapy With or Without Cisplatin and Paclitaxel After Total Abdominal Hysterectomy and Bilateral Salpingo-oophorectomy in Patients With Stage I or II Endometrial Cancer (also RTOG 9905) | Terminated |
| GOG-9902 | Quality of Life of Gynecologic Cancer Survivors | |
| GOG-9805 | Phase II Study of Amifostine for Protection Against Cisplatin and Paclitaxel Induced Neurotoxicity in Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | PMID 14615449 |
| GOG-9405 | Phase I Study of Paclitaxel Combined with Fixed Doses of CDDP/DOX for Advanced Gynecologic Malignancies and Recurrent Bladder Cancer with or without Pelvic Irradiation | PMID 11181665 |
| GOG-9403 | Phase I Dose-Seeking Study of TAX Administered During Pelvic Irradiation for Advanced or Recurrent Cancer of the Cervix, Vagina, Endometrium, or Bladder | |
| GOG-9301 | Phase I Study of Weekly CDDP and Whole-Abdominal Radiotherapy Followed by DOX/CDDP in Patients with Stage III/IV Endometrial Carcinoma | PMID 15385116 |
| GOG-9206 | Phase II Study of Laparoscopic-Assisted Vaginal Hysterectomy/Bilateral Salpingo-Oophorectomy, Intraperitoneal Staging, and Pelvic and Aortic Lymph Node Sampling in Patients with Presumed Stage I/IIA Adenocarcinoma of the Endometrium | PMID 15086735 |
| GOG-9102 | The Effect of Alopecia on the Cancer Patient's Body Image and the Role of Audiovisual Information on Improving Body Image | |
| GOG-9101 | Phase I Study of Intraperitoneal TAX in Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma | PMID 8523061 |
| GOG-9001 | Phase I Limited-Access Study of Weekly Cisplatin and Whole-Abdominal Irradiation in Patients with Stage III/IV Endometrial Carcinoma | PMID 8946862 |
| GOG-8909 | Phase I Study of CDDP plus Cyclosporine in Patients with Refractory Gynecologic Cancer | |
| GOG-8808 | Phase I Study of Intraperitoneal Taxol in Patients with Recurrent and/or Persistent Gynecologic Carcinoma | PMID 7912515 |
| GOG-7892 | Phase II Hormone Therapy with Tamoxifen for Advanced or Recurrent Endometrial Adenocarcinoma | Terminated |
| GOG-180 | Phase II Study of Danazol in Patients with Advanced or Recurrent Endometrial Cancer | PMID 12798713 |
| GOG-168 | Phase II Study of Anastrozole (Arimidex) in Advanced, Recurrent or Persistent Endometrial Cancer | PMID 10926805 |
| GOG-167 | Prospective Study of Immediate Hysterectomy and Phase II Randomized Study of Medroxyprogesterone Acetate (Provera) Versus Medroxyprogesterone Acetate Suspension (Depo-Provera) Prior to Hysterectomy in Patients With Atypical Endometrial Hyperplasia | PMID 16400639 |
| GOG-166 | Phase II Study of High-Dose Intravenous Progesterone and Doxorubicin for Progressive Endometrial Carcinoma Resistant to Ongoing Doxorubicin Alone | |
| GOG-159 | Phase II Study of ZDX in Advanced, Recurrent, or Persistent Endometrial Cancer | |
| GOG-153 | Phase II Study of Alternating Courses of Megestrol and Tamoxifen for Recurrent or Persistent Endometrial Adenocarcinoma | PMID 14751131 |
| GOG-147 | Companion Protocol to Evaluate the Quality of Life in Patients with Advanced Endometrial Cancer Simultaneously Enrolled on GOG-122 | |
| GOG-139 | Phase III Randomized Study of DOX/CDDP Administered on Standard vs Circadian-Timed Schedules in Patients with Primary Stage III/IV/Recurrent Endometrial Carcinoma | PMID 14551299 |
| GOG-129L | Phase II Study of 6-Hydroxymethylacylfulvene (Irofulven) in Patients With Persistent or Recurrent, Refractory Endometrial Carcinoma | PMID 15122083 |
| GOG-129J | Phase II Study of Topotecan in Patients With Persistent, Recurrent, or Refractory Endometrial Carcinoma | PMID 12468321 |
| GOG-129I | Phase II Study of Pyrazoloacridine (PZA) in Patients with Recurrent or Refractory Endometrial Carcinoma | PMID 11812081 |
| GOG-129H | Phase II Study of the Effects of DOXIL in the Treatment of Recurrent or Persistent Endometrial Carcinoma | PMID 11981008 |
| GOG-129E | Phase II Study of Dactinomycin for Recurrent or Persistent Endometrial Carcinoma | PMID 10600310 |
| GOG-129C | Phase II Study of TAX for Recurrent or Persistent Endometrial Cancer | PMID 12648575 |
| GOG-129B | Phase II Study of Prolonged Oral VP-16 in Patients with Recurrent or Advanced Endometrial Cancer | |
| GOG-122 | Phase III Randomized Trial of Whole-Abdominal Irradiation vs DOX/CDDP in Patients Who Have Undergone Maximum Debulking of Advanced Endometrial Carcinoma | PMID 16330675 |
| GOG-121 | Phase II Trial of High-Dose MEG in Patients with Advanced or Recurrent Endometrial Carcinoma | |
| GOG-119 | Phase II Study of Tamoxifen plus Medroxyprogesterone for Advanced, Recurrent, or Metastatic Endometrial Carcinoma | PMID 14751130 |
| GOG-107 | Phase III Randomized Study Comparing ADR vs ADR/CACP in Patients with Recurrent Primary Stage III/IV Endometrial Carcinoma | PMID 15459211 |
| GOG-99 | Phase III Randomized Evaluation of Adjuvant Postoperative Pelvic Radiotherapy vs No Adjuvant Therapy for Surgical Stage I and Occult Stage II Intermediate-Risk Endometrial Carcinoma | PMID 14984936 |
| GOG-96 | Phase II Circadian-Timed Combination Chemotherapy with ADR/CDDP in Patients with Advanced Primary Endometrial Carcinoma | PMID 8256764 |
| GOG-94 | Phase II Study of Whole-Abdominal Radiotherapy in Patients with Papillary Serous Carcinoma and Clear Cell Carcinoma of the Endometrium or with Maximally Debulked Advanced Endometrial Carcinoma | PMID 16213007 |
| GOG-860 | Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- TAX/G-CSF | |
| GOG-86J | Phase II Master Protocol for Treatment of Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Tumor Necrosis Factor | |
| GOG-86I | Phase II Study of IFF/Mesna for Advanced or Recurrent Carcinoma of the Endometrium | |
| GOG-86E | Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Vincristine | PMID 8424397 |
| GOG-86D | Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- MTX | PMID 2407104 |
| GOG-86 | Phase II Master Protocol for Advanced or Recurrent Carcinoma of the Endometrium: Phase I/II Study of Hexamethylmelamine | PMID 3141250 |
| GOG-083 | Phase II Clinico-Pathological Study of Adjuvant Chemotherapy with L-PAM in Patients with Simultaneous Endometrial and Ovarian Carcinoma | |
| GOG-81F | Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase II Tamoxifen for Disease Responsive to Progestins | PMID 11208827 |
| GOG-81 | Phase III Randomized Study of Low-Dose vs High-Dose Medroxyprogesterone Acetate (Provera) in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma | PMID 11208827 |
| GOG-62 | Data Collection Form for Extravasation Injury with Doxorubicin | |
| GOG-48 | Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer | PMID 8021731 |
| GOG-28 | Phase III L-PAM/5-FU/MEG Chemotherapy vs ADR/CTX/5-FU/MEG for Primary Stage III or IV Recurrent or Residual Endometrial Cancer | PMID 6371627 |
| GOG-34 | Phase III Randomized Trial of Surgery plus Radiotherapy Followed by Chemotherapy with ADR vs Surgery plus Radiotherapy Alone in Patients with High-Risk Stage I/High-Risk Occult Stage II Endometrial Carcinoma, Including Those with Adnexal Metastases | PMID 2298404 |
| GOG-30 | Phase II Chemotherapy with Adriamycin for Endometrial Adenocarcinoma | |
| GOG-26MM | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: EDAM | PMID 7900709 |
| GOG-26KK | Phase II Master Protocol for Advanced, Recurrent Endometrial Carcinoma: Merbarone | PMID 8554040 |
| GOG-26HH | Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fluorouracil/Leucovorin | |
| GOG-26GG | Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fazarabine | PMID 7534978 |
| GOG-26Y | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Vinblastine | PMID 2239800 |
| GOG-26W | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Echinomycin | PMID 2198794 |
| GOG-26V | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: N-Methylformamide | PMID 2384305 |
| GOG-26T | Phase II Master Protocol Chemotherapy with 4'-Deoxydoxorubicin for Advanced, Recurrent Pelvic Malignancies | PMID 2557300 |
| GOG-26P | Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: AT-125 | PMID 3700040 |
| GOG-26M | Phase II Chemotherapy with PALA for Advanced Recurrent Pelvic Malignancies | PMID 6731346 |
| GOG-26K | Phase II Chemotherapy with Chlorozotocin for Advanced, Recurrent and Metastatic Pelvic Malignancies in Progression | |
| GOG-26J | Phase II Chemotherapy with YOSHI-864 for Advanced, Recurrent Pelvic Malignancies | PMID 6288239 |
| GOG-26H | Phase II Chemotherapy with Maytansine for Advanced Recurrent Pelvic Malignancies | PMID 6869315 |
| GOG-26I | Phase II Chemotherapy with AMSA for Advanced, Recurrent Pelvic Malignancies (Cervix) | PMID 6687445 |
| GOG-26G | Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: ICRF-159 | PMID 3953488 |
| GOG-26F | Phase II Chemotherapy with Baker's Antifol for Advanced Recurrent Pelvic Malignancies | PMID 6236163 |
| GOG-26E | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Dianhydrogalactitol | PMID 6511240 |
| GOG-26D | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: VP-16 | PMID 6509456 |
| GOG-26B | Phase II Chemotherapy with Piperazinedione for Advanced Gynecologic Malignancies in Women | PMID 3754086 |
| GOG-23 | Chemotherapy with ADR/VCR/CTX for Carcinoma of the Cervix and for Adenocarcinoma of the Endometrium | |
| GOG-18 | Multimodality Therapy with Surgery and Radiotherapy for Stage II Adenocarcinoma and Adeno-Acanthoma of the Endometrium | Terminated |
| GOG-17 | Radiotherapy plus Endocrine Therapy with Progestin for Stage III and Stage IV Adenocarcinoma of the Endometrium | Terminated |
| GOG-16 | Preoperative vs Postoperative Radiotherapy Adjunctive to Surgery for Stage I Adenocarcinoma of the Endometrium | Terminated |
| GOG-15 | Modified Phase II-III Chemotherapy with CCNU or MeCCNU for Advanced Gynecologic Cancers | PMID 350400 |
| GOG-P12 | Relation of Progestin Receptor Concentration to Efficacy of Progestin Therapy for Endometrial Adenocarcinoma - Pilot Study | |